schliessen

Filtern

 

Bibliotheken

Effect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease

PurposeActivation of the rennin–angiotensin system (RAS) is thought to contribute to hypertension and proteinuria, and eventually to the progression of chronic kidney disease (CKD). Recent evidence suggests that urinary angiotensinogen (UAGT) excretion reflects activation of the intrarenal RAS. This... Full description

Journal Title: Postgraduate medical journal 2011-10, Vol.87 (1032), p.664-669
Main Author: Lee, Yu-Ji
Other Authors: Cho, Seong , Kim, Sung Rok , Jang, Hye Ryoun , Lee, Jung Eun , Huh, Wooseong , Kim, Dae Joong , Oh, Ha Young , Kim, Yoon-Goo
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: London: The Fellowship of Postgraduate Medicine
ID: ISSN: 0032-5473
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_894815981
title: Effect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease
format: Article
creator:
  • Lee, Yu-Ji
  • Cho, Seong
  • Kim, Sung Rok
  • Jang, Hye Ryoun
  • Lee, Jung Eun
  • Huh, Wooseong
  • Kim, Dae Joong
  • Oh, Ha Young
  • Kim, Yoon-Goo
subjects:
  • Adult
  • Angiotensin II receptor blocker
  • Angiotensin II Type 1 Receptor Blockers - therapeutic use
  • angiotensinogen
  • Angiotensinogen - blood
  • Angiotensinogen - urine
  • biochemistry
  • Biological and medical sciences
  • Chemical properties
  • Diabetes. Impaired glucose tolerance
  • Endocrine pancreas. Apud cells (diseases)
  • Endocrinopathies
  • Enzyme-Linked Immunosorbent Assay
  • Etiopathogenesis. Screening. Investigations. Target tissue resistance
  • Female
  • Follow-Up Studies
  • General aspects
  • Humans
  • Kidney Failure, Chronic - drug therapy
  • Kidney Failure, Chronic - urine
  • Losartan
  • Losartan - therapeutic use
  • Male
  • Measurement
  • Medical sciences
  • Middle Aged
  • nephrology
  • Nephrology. Urinary tract diseases
  • non-diabetic chronic kidney disease
  • Proteinuria
  • Proteinuria - drug therapy
  • renal function
  • Renin-Angiotensin System - drug effects
  • Research
  • Urinary system involvement in other diseases. Miscellaneous
  • Urinary tract. Prostate gland
  • Urine
ispartof: Postgraduate medical journal, 2011-10, Vol.87 (1032), p.664-669
description: PurposeActivation of the rennin–angiotensin system (RAS) is thought to contribute to hypertension and proteinuria, and eventually to the progression of chronic kidney disease (CKD). Recent evidence suggests that urinary angiotensinogen (UAGT) excretion reflects activation of the intrarenal RAS. This study was performed to determine the effect of losartan on proteinuria and UAGT excretion in non-diabetic patients with CKD with non-nephrotic-range proteinuria.Study designThirty-two patients with non-nephrotic-range proteinuria (0.045–0.23 g/mmol creatinine) and normal renal function between April 2005 and April 2006 were randomised to a losartan (n=17) or a control (n=15) group. Patients in the losartan group received losartan 50 mg/day, and the doses were titrated up to 100 mg/day after 6 weeks. Serum and urinary angiotensinogen concentrations were measured by sandwich ELISA. The primary end point was the percentage change in proteinuria. The secondary end points were changes in estimated glomerular filtration rate and UAGT excretion. The follow-up period was 24 months.ResultsBaseline characteristics in the two groups were similar. After 24 months, losartan had reduced urinary protein excretion by 43% (from mean±SD 0.13±0.04 to 0.073±0.03 g/mmol, p
language: eng
source:
identifier: ISSN: 0032-5473
fulltext: no_fulltext
issn:
  • 0032-5473
  • 1469-0756
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.2629037
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_894815981
sourceformatXML
sourcesystemPC
galeidA269950273
sourcerecordidA269950273
originalsourceidFETCH-LOGICAL-b459t-d953a4fdad154ab81fb4427c7de6cf4c1a60155f2d805ea7b8975e91cae96f0
addsrcrecordideNqFkc1rFDEYxgdR7Fq9e5KAiAeZNZnJx-TYLtUKRQ-K1_BOPrbZziZrksUW_OPNMmuFHpQcJnnze9553jxN85LgJSE9f79bbzfLDhNSjwNm8lGzIJTLFgvGHzcLjPuuZVT0J82znDcYk15Q8rQ56YggjIlu0fy6cM7qgqJDU8yQCgQUA9qlWKwP--QBQTCobgKku7pf-3oTsg9xbQOytzrZ4qvCBxRiaI2HsRY02kHxNpSMfvpyjfR1iqFWb7wJ9g4Zny1k-7x54mDK9sXxe9p8_XDxbXXZXn35-Gl1dtWOlMnSGsl6oM6AIYzCOBA3UtoJLYzl2lFNgOM6jutMfQMLYhykYFYSDVZyh0-bt3PXOtSPvc1FbX3Wdpog2LjPapB0IEwOpJKvH5CbuE-hWlNEDIRT2WNZqeVMrWGyygcXSwJdl7Fbr2Owztf6WcelZLgTfRXgWaBTzDlZp3bJb-tzKoLVIUd1yFEdclRzjlXy6uhkP26tuRf8Ca4Cb44AZA2TSxC0z385yoTsCK4cf_Bv7QscEqum_fQvB-0s9LnY2_vGkG4UF71g6vP3leIr2Z3zS6oOht7N_Fgb_Xe-3wom1mE
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1781649309
display
typearticle
titleEffect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease
creatorLee, Yu-Ji ; Cho, Seong ; Kim, Sung Rok ; Jang, Hye Ryoun ; Lee, Jung Eun ; Huh, Wooseong ; Kim, Dae Joong ; Oh, Ha Young ; Kim, Yoon-Goo
creatorcontribLee, Yu-Ji ; Cho, Seong ; Kim, Sung Rok ; Jang, Hye Ryoun ; Lee, Jung Eun ; Huh, Wooseong ; Kim, Dae Joong ; Oh, Ha Young ; Kim, Yoon-Goo
descriptionPurposeActivation of the rennin–angiotensin system (RAS) is thought to contribute to hypertension and proteinuria, and eventually to the progression of chronic kidney disease (CKD). Recent evidence suggests that urinary angiotensinogen (UAGT) excretion reflects activation of the intrarenal RAS. This study was performed to determine the effect of losartan on proteinuria and UAGT excretion in non-diabetic patients with CKD with non-nephrotic-range proteinuria.Study designThirty-two patients with non-nephrotic-range proteinuria (0.045–0.23 g/mmol creatinine) and normal renal function between April 2005 and April 2006 were randomised to a losartan (n=17) or a control (n=15) group. Patients in the losartan group received losartan 50 mg/day, and the doses were titrated up to 100 mg/day after 6 weeks. Serum and urinary angiotensinogen concentrations were measured by sandwich ELISA. The primary end point was the percentage change in proteinuria. The secondary end points were changes in estimated glomerular filtration rate and UAGT excretion. The follow-up period was 24 months.ResultsBaseline characteristics in the two groups were similar. After 24 months, losartan had reduced urinary protein excretion by 43% (from mean±SD 0.13±0.04 to 0.073±0.03 g/mmol, p<0.0001), but proteinuria had not changed in the control group. The percentage change in mean arterial pressure did not differ between the groups. Losartan decreased logarithmically converted UAGT excretion (from 1.58±0.47 to 1.00±0.52, p=0.001). Estimated glomerular filtration rate decreased significantly only in the control group.ConclusionLosartan significantly decreased proteinuria and UAGT excretion, and preserved renal function in non-diabetic patients with CKD.
identifier
0ISSN: 0032-5473
1EISSN: 1469-0756
2DOI: 10.1136/pgmj.2011.118059
3PMID: 21715572
languageeng
publisherLondon: The Fellowship of Postgraduate Medicine
subjectAdult ; Angiotensin II receptor blocker ; Angiotensin II Type 1 Receptor Blockers - therapeutic use ; angiotensinogen ; Angiotensinogen - blood ; Angiotensinogen - urine ; biochemistry ; Biological and medical sciences ; Chemical properties ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Enzyme-Linked Immunosorbent Assay ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; Follow-Up Studies ; General aspects ; Humans ; Kidney Failure, Chronic - drug therapy ; Kidney Failure, Chronic - urine ; Losartan ; Losartan - therapeutic use ; Male ; Measurement ; Medical sciences ; Middle Aged ; nephrology ; Nephrology. Urinary tract diseases ; non-diabetic chronic kidney disease ; Proteinuria ; Proteinuria - drug therapy ; renal function ; Renin-Angiotensin System - drug effects ; Research ; Urinary system involvement in other diseases. Miscellaneous ; Urinary tract. Prostate gland ; Urine
ispartofPostgraduate medical journal, 2011-10, Vol.87 (1032), p.664-669
rights
02011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
12015 INIST-CNRS
2Copyright: 2011 (c) 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
lds50peer_reviewed
citedbyFETCH-LOGICAL-b459t-d953a4fdad154ab81fb4427c7de6cf4c1a60155f2d805ea7b8975e91cae96f0
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24579210$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21715572$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Lee, Yu-Ji
1Cho, Seong
2Kim, Sung Rok
3Jang, Hye Ryoun
4Lee, Jung Eun
5Huh, Wooseong
6Kim, Dae Joong
7Oh, Ha Young
8Kim, Yoon-Goo
title
0Effect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease
1Postgraduate medical journal
addtitlePostgrad Med J
descriptionPurposeActivation of the rennin–angiotensin system (RAS) is thought to contribute to hypertension and proteinuria, and eventually to the progression of chronic kidney disease (CKD). Recent evidence suggests that urinary angiotensinogen (UAGT) excretion reflects activation of the intrarenal RAS. This study was performed to determine the effect of losartan on proteinuria and UAGT excretion in non-diabetic patients with CKD with non-nephrotic-range proteinuria.Study designThirty-two patients with non-nephrotic-range proteinuria (0.045–0.23 g/mmol creatinine) and normal renal function between April 2005 and April 2006 were randomised to a losartan (n=17) or a control (n=15) group. Patients in the losartan group received losartan 50 mg/day, and the doses were titrated up to 100 mg/day after 6 weeks. Serum and urinary angiotensinogen concentrations were measured by sandwich ELISA. The primary end point was the percentage change in proteinuria. The secondary end points were changes in estimated glomerular filtration rate and UAGT excretion. The follow-up period was 24 months.ResultsBaseline characteristics in the two groups were similar. After 24 months, losartan had reduced urinary protein excretion by 43% (from mean±SD 0.13±0.04 to 0.073±0.03 g/mmol, p<0.0001), but proteinuria had not changed in the control group. The percentage change in mean arterial pressure did not differ between the groups. Losartan decreased logarithmically converted UAGT excretion (from 1.58±0.47 to 1.00±0.52, p=0.001). Estimated glomerular filtration rate decreased significantly only in the control group.ConclusionLosartan significantly decreased proteinuria and UAGT excretion, and preserved renal function in non-diabetic patients with CKD.
subject
0Adult
1Angiotensin II receptor blocker
2Angiotensin II Type 1 Receptor Blockers - therapeutic use
3angiotensinogen
4Angiotensinogen - blood
5Angiotensinogen - urine
6biochemistry
7Biological and medical sciences
8Chemical properties
9Diabetes. Impaired glucose tolerance
10Endocrine pancreas. Apud cells (diseases)
11Endocrinopathies
12Enzyme-Linked Immunosorbent Assay
13Etiopathogenesis. Screening. Investigations. Target tissue resistance
14Female
15Follow-Up Studies
16General aspects
17Humans
18Kidney Failure, Chronic - drug therapy
19Kidney Failure, Chronic - urine
20Losartan
21Losartan - therapeutic use
22Male
23Measurement
24Medical sciences
25Middle Aged
26nephrology
27Nephrology. Urinary tract diseases
28non-diabetic chronic kidney disease
29Proteinuria
30Proteinuria - drug therapy
31renal function
32Renin-Angiotensin System - drug effects
33Research
34Urinary system involvement in other diseases. Miscellaneous
35Urinary tract. Prostate gland
36Urine
issn
00032-5473
11469-0756
fulltextfalse
rsrctypearticle
creationdate2011
recordtypearticle
recordideNqFkc1rFDEYxgdR7Fq9e5KAiAeZNZnJx-TYLtUKRQ-K1_BOPrbZziZrksUW_OPNMmuFHpQcJnnze9553jxN85LgJSE9f79bbzfLDhNSjwNm8lGzIJTLFgvGHzcLjPuuZVT0J82znDcYk15Q8rQ56YggjIlu0fy6cM7qgqJDU8yQCgQUA9qlWKwP--QBQTCobgKku7pf-3oTsg9xbQOytzrZ4qvCBxRiaI2HsRY02kHxNpSMfvpyjfR1iqFWb7wJ9g4Zny1k-7x54mDK9sXxe9p8_XDxbXXZXn35-Gl1dtWOlMnSGsl6oM6AIYzCOBA3UtoJLYzl2lFNgOM6jutMfQMLYhykYFYSDVZyh0-bt3PXOtSPvc1FbX3Wdpog2LjPapB0IEwOpJKvH5CbuE-hWlNEDIRT2WNZqeVMrWGyygcXSwJdl7Fbr2Owztf6WcelZLgTfRXgWaBTzDlZp3bJb-tzKoLVIUd1yFEdclRzjlXy6uhkP26tuRf8Ca4Cb44AZA2TSxC0z385yoTsCK4cf_Bv7QscEqum_fQvB-0s9LnY2_vGkG4UF71g6vP3leIr2Z3zS6oOht7N_Fgb_Xe-3wom1mE
startdate201110
enddate201110
creator
0Lee, Yu-Ji
1Cho, Seong
2Kim, Sung Rok
3Jang, Hye Ryoun
4Lee, Jung Eun
5Huh, Wooseong
6Kim, Dae Joong
7Oh, Ha Young
8Kim, Yoon-Goo
general
0The Fellowship of Postgraduate Medicine
1BMJ Publishing Group
2BMJ Publishing Group Ltd
3BMJ Publishing Group LTD
scope
0BSCLL
1IQODW
2CGR
3CUY
4CVF
5ECM
6EIF
7NPM
8AAYXX
9CITATION
10BSHEE
113V.
127X7
137XB
1488E
1588I
168AF
178FI
188FJ
198FK
20ABUWG
21AZQEC
22BENPR
23BTHHO
24DWQXO
25FYUFA
26GHDGH
27GNUQQ
28HCIFZ
29K9.
30M0S
31M1P
32M2P
33PQEST
34PQQKQ
35PQUKI
36PRINS
37Q9U
387X8
sort
creationdate201110
titleEffect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease
authorLee, Yu-Ji ; Cho, Seong ; Kim, Sung Rok ; Jang, Hye Ryoun ; Lee, Jung Eun ; Huh, Wooseong ; Kim, Dae Joong ; Oh, Ha Young ; Kim, Yoon-Goo
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-b459t-d953a4fdad154ab81fb4427c7de6cf4c1a60155f2d805ea7b8975e91cae96f0
rsrctypearticles
prefilterarticles
languageeng
creationdate2011
topic
0Adult
1Angiotensin II receptor blocker
2Angiotensin II Type 1 Receptor Blockers - therapeutic use
3angiotensinogen
4Angiotensinogen - blood
5Angiotensinogen - urine
6biochemistry
7Biological and medical sciences
8Chemical properties
9Diabetes. Impaired glucose tolerance
10Endocrine pancreas. Apud cells (diseases)
11Endocrinopathies
12Enzyme-Linked Immunosorbent Assay
13Etiopathogenesis. Screening. Investigations. Target tissue resistance
14Female
15Follow-Up Studies
16General aspects
17Humans
18Kidney Failure, Chronic - drug therapy
19Kidney Failure, Chronic - urine
20Losartan
21Losartan - therapeutic use
22Male
23Measurement
24Medical sciences
25Middle Aged
26nephrology
27Nephrology. Urinary tract diseases
28non-diabetic chronic kidney disease
29Proteinuria
30Proteinuria - drug therapy
31renal function
32Renin-Angiotensin System - drug effects
33Research
34Urinary system involvement in other diseases. Miscellaneous
35Urinary tract. Prostate gland
36Urine
toplevelpeer_reviewed
creatorcontrib
0Lee, Yu-Ji
1Cho, Seong
2Kim, Sung Rok
3Jang, Hye Ryoun
4Lee, Jung Eun
5Huh, Wooseong
6Kim, Dae Joong
7Oh, Ha Young
8Kim, Yoon-Goo
collection
0Istex
1Pascal-Francis
2Medline
3MEDLINE
4MEDLINE (Ovid)
5MEDLINE
6MEDLINE
7PubMed
8CrossRef
9Academic OneFile (A&I only)
10ProQuest Central (Corporate)
11Health & Medical Collection
12ProQuest Central (purchase pre-March 2016)
13Medical Database (Alumni Edition)
14Science Database (Alumni Edition)
15STEM Database
16Hospital Premium Collection
17Hospital Premium Collection (Alumni Edition)
18ProQuest Central (Alumni) (purchase pre-March 2016)
19ProQuest Central (Alumni Edition)
20ProQuest Central Essentials
21ProQuest Central
22BMJ Journals
23ProQuest Central Korea
24Health Research Premium Collection
25Health Research Premium Collection (Alumni)
26ProQuest Central Student
27SciTech Premium Collection
28ProQuest Health & Medical Complete (Alumni)
29Health & Medical Collection (Alumni Edition)
30Medical Database
31Science Database
32ProQuest One Academic Eastern Edition
33ProQuest One Academic
34ProQuest One Academic UKI Edition
35ProQuest Central China
36ProQuest Central Basic
37MEDLINE - Academic
jtitlePostgraduate medical journal
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Lee, Yu-Ji
1Cho, Seong
2Kim, Sung Rok
3Jang, Hye Ryoun
4Lee, Jung Eun
5Huh, Wooseong
6Kim, Dae Joong
7Oh, Ha Young
8Kim, Yoon-Goo
formatjournal
genrearticle
ristypeJOUR
atitleEffect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease
jtitlePostgraduate medical journal
addtitlePostgrad Med J
date2011-10
risdate2011
volume87
issue1032
spage664
epage669
pages664-669
issn0032-5473
eissn1469-0756
abstractPurposeActivation of the rennin–angiotensin system (RAS) is thought to contribute to hypertension and proteinuria, and eventually to the progression of chronic kidney disease (CKD). Recent evidence suggests that urinary angiotensinogen (UAGT) excretion reflects activation of the intrarenal RAS. This study was performed to determine the effect of losartan on proteinuria and UAGT excretion in non-diabetic patients with CKD with non-nephrotic-range proteinuria.Study designThirty-two patients with non-nephrotic-range proteinuria (0.045–0.23 g/mmol creatinine) and normal renal function between April 2005 and April 2006 were randomised to a losartan (n=17) or a control (n=15) group. Patients in the losartan group received losartan 50 mg/day, and the doses were titrated up to 100 mg/day after 6 weeks. Serum and urinary angiotensinogen concentrations were measured by sandwich ELISA. The primary end point was the percentage change in proteinuria. The secondary end points were changes in estimated glomerular filtration rate and UAGT excretion. The follow-up period was 24 months.ResultsBaseline characteristics in the two groups were similar. After 24 months, losartan had reduced urinary protein excretion by 43% (from mean±SD 0.13±0.04 to 0.073±0.03 g/mmol, p<0.0001), but proteinuria had not changed in the control group. The percentage change in mean arterial pressure did not differ between the groups. Losartan decreased logarithmically converted UAGT excretion (from 1.58±0.47 to 1.00±0.52, p=0.001). Estimated glomerular filtration rate decreased significantly only in the control group.ConclusionLosartan significantly decreased proteinuria and UAGT excretion, and preserved renal function in non-diabetic patients with CKD.
copLondon
pubThe Fellowship of Postgraduate Medicine
pmid21715572
doi10.1136/pgmj.2011.118059